COPD Exacerbations: How to Prevent Flare-Ups, What's New in 2026, and Why Your Sleep Matters

November is COPD Awareness Month, and it is a good moment to talk about the part of COPD that does the most damage: the flare-up. Chronic obstructive pulmonary disease is a slowly progressive condition, but its trajectory is rarely smooth. For most patients, lung function and quality of life decline in steps — and each step is an exacerbation, a sudden worsening of breathing symptoms that lasts days to weeks.

The goal of modern COPD care is no longer just “feel a bit better on an inhaler.” It is to prevent the next exacerbation. The 2026 GOLD (Global Initiative for Chronic Obstructive Lung Disease) report makes this explicit, and several new treatments — including two biologics approved in the last two years — give us more tools than we have ever had.

Why Exacerbations Matter So Much

COPD is the sixth leading cause of death in the United States according to CDC data, and the burden is largely driven by flare-ups. Even a single moderate exacerbation is associated with a higher risk of a major cardiac event — arrhythmia, heart failure, heart attack, or stroke — in the following 30 days. Exacerbations accelerate lung function decline, hospitalizations are followed by high rates of readmission, and many patients never fully return to their previous baseline.

What Counts as an Exacerbation?

An exacerbation is an acute worsening of respiratory symptoms — more shortness of breath, more cough, or a change in the amount or color of sputum — beyond your normal day-to-day variation, requiring a change in treatment. They are graded by severity:

• Mild: managed by increasing your rescue inhaler.
• Moderate: requires a course of oral steroids and/or antibiotics.
• Severe: requires an emergency department visit or hospital admission.

The 2026 GOLD report sharpens this definition, in part because roughly one-third of patients hospitalized with a COPD label are actually admitted for something else — heart failure, pneumonia, a blood clot in the lung, or an arrhythmia can all look like a COPD flare. Getting the diagnosis right matters, because the treatment is different.

Warning Signs: Act Early

Patients who start treatment early in a flare recover faster and are less likely to be hospitalized. Call our office the same day if you notice:

• Breathing that is noticeably worse than your usual baseline, or needing your rescue inhaler more often than normal
• Increased cough, or sputum that is greater in volume, thicker, or has turned yellow or green
• Increased wheezing or chest tightness
• New leg swelling, fever, or unusual fatigue
• Waking at night short of breath, or morning headaches (see the sleep section below)

How Exacerbations Are Treated

Treatment of an acute flare has been well standardized for years, and the principle is to treat quickly and briefly:

• Short-acting bronchodilators (albuterol with or without ipratropium) to open the airways.
• A short course of oral corticosteroids — typically prednisone 40 mg daily for 5 days. Longer courses add side effects without added benefit.
• Antibiotics when appropriate — generally when sputum becomes more purulent along with increased volume or breathlessness, or when a patient needs ventilatory support. Not every flare is bacterial, and we try to avoid unnecessary antibiotics.
• Carefully titrated oxygen — aiming for a saturation of about 88–92%. More is not better in COPD; excess oxygen can worsen carbon dioxide retention.
• Noninvasive ventilation (BiPAP) for patients with respiratory acidosis from CO₂ retention, which reduces the need for intubation and improves survival.

The New Goal: Disease Stability

One of the most important ideas in GOLD 2026 is disease stability — defined as no exacerbations, no worsening symptoms, and no lung function decline beyond what is expected with normal aging. Rather than waiting for a hospitalization before changing therapy, the report encourages escalating treatment whenever a patient falls short of stability. In clinical trial populations, only a minority of patients with prior exacerbations achieve a full year of stability on triple inhaled therapy, which tells us how much room there still is to improve — and patients who do reach stability have meaningfully better outcomes afterward.

Preventing the Next Flare: What Actually Works

1. The right inhaler, used the right way

For patients with frequent exacerbations, GOLD supports long-acting bronchodilator combinations, with escalation to triple therapy (LABA + LAMA + inhaled corticosteroid) in those whose blood eosinophil counts suggest they will benefit. A surprising number of flares trace back to poor inhaler technique, an inhaler that does not match the patient's inspiratory effort, or cost-related skipping of doses. We review technique at visits and can help with insurance and device choice.

2. Biologics for eosinophilic COPD

This is the biggest recent change. For patients who keep exacerbating despite triple inhaled therapy and have elevated blood eosinophils, two biologics are now FDA-approved as add-on treatment:

• Dupilumab (Dupixent), approved in 2024. In the BOREAS and NOTUS phase 3 trials, it reduced moderate or severe exacerbations by roughly 30% and improved lung function and quality of life in patients with blood eosinophils of 300 cells/µL or higher.
• Mepolizumab (Nucala), approved in May 2025 as a once-monthly injection. In the MATINEE trial, it reduced moderate or severe exacerbations by about 21% compared with placebo.

These are not for everyone, and a simple blood count helps identify candidates. Importantly, they are not immunosuppressants in the way many rheumatology drugs are. Our asthma-biologic experience (see our article on advanced asthma biologics) carries over directly to this population.

3. Other add-on options

For patients who continue to flare on appropriate inhaled therapy, GOLD also lists roflumilast (an oral anti-inflammatory for those with chronic bronchitis and prior hospitalization) and long-term azithromycin (most effective in former smokers, with monitoring for QT prolongation, hearing changes, and antibiotic resistance). Ensifentrine (Ohtuvayre), a nebulized dual PDE3/4 inhibitor approved in 2024, improves breathlessness and lung function as an add-on, though its role in preventing flares is less established.

4. Pulmonary rehabilitation

Rehabilitation is among the most effective interventions in COPD, and it works at every stage. Starting a program within weeks of leaving the hospital reduces readmissions and improves exercise capacity. Despite this, access is limited for many patients — so tell us if you have never been referred.

5. Vaccines and infection prevention

Respiratory infections trigger a large share of exacerbations. Stay current with annual influenza vaccination, an updated COVID-19 vaccine, pneumococcal vaccination, and RSV vaccination (the CDC recommends it for adults 75 and older and for adults 50–74 at increased risk, which includes chronic lung disease). Vaccines are not a replacement for treatment, but every infection avoided is a flare avoided.

6. Stopping smoking and limiting exposures

Quitting remains the single intervention that slows lung function decline. Also pay attention to air quality — wildfire smoke is a real risk in Southern California (see our article on wildfire smoke and lung health).

7. Procedures for selected emphysema patients

For patients with severe emphysema and hyperinflation who remain breathless despite optimal therapy, bronchoscopic lung volume reduction can improve breathing and reduce exacerbations. Read more in our article on Zephyr valves for emphysema.

The Sleep Connection: COPD–OSA Overlap

Because PulmoCrit physicians are board-certified in both pulmonary and sleep medicine, we look at something many COPD programs overlook: what happens to your lungs while you sleep.

Both COPD and obstructive sleep apnea (OSA) are common, so many people have both — a combination known as overlap syndrome. Patients with overlap syndrome have worse nighttime oxygen levels than those with either condition alone, higher rates of pulmonary hypertension and right heart strain, and in observational studies more exacerbation-related hospitalizations and higher mortality. In one cohort of patients with COPD and significant sleep-disordered breathing, 5-year survival was 71% with CPAP plus oxygen compared with 26% with oxygen alone. These were observational data, not a randomized trial, but the signal has been consistent: untreated overlap syndrome is dangerous, and treating it helps.

Even without OSA, COPD patients often experience prolonged dips in oxygen during sleep — particularly during REM — that daytime readings do not capture. Sleeping poorly makes a flare feel worse, and recurrent nocturnal hypoxemia and CO₂ retention strain the heart. Signs that sleep may be part of the problem include loud snoring, witnessed pauses in breathing, morning headaches, daytime sleepiness, and waking short of breath.

Home ventilation after a severe flare

For a subset of patients who retain carbon dioxide (hypercapnia) and are hospitalized with a severe exacerbation, the HOT-HMV trial showed that adding home noninvasive ventilation (high-intensity BiPAP) to oxygen roughly tripled the median time to readmission or death — 4.3 months versus 1.4 months with oxygen alone. This is why we pay attention to carbon dioxide levels after hospitalization and may recommend a sleep or ventilation evaluation. If you use BiPAP, our article on CPAP vs. BiPAP explains the differences.

Your COPD Action Plan

Every COPD patient should leave their visit with a written plan covering the following:

• What your normal looks like, so you can recognize a change early
• Which symptoms mean you should call us the same day, and which mean the ER
• Your daily inhalers, with technique checked at every visit
• A plan for rescue medications, if appropriate, so treatment starts promptly
• Your vaccine schedule and a pulmonary rehabilitation referral
• A sleep assessment if you snore, wake unrefreshed, or have morning headaches
• A follow-up visit within a few weeks of any flare, ER visit, or hospitalization

If you have had two or more moderate flares or one hospitalization in the past year, that is a clear signal that your current regimen deserves a fresh look. COPD is treatable, and preventing exacerbations is more achievable now than at any point in the past.

This article is for general education and is not a substitute for individual medical advice. If you are having a medical emergency, call 911.